In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor Running title: CD23 CAR-targeting for CLL immunotherapy Keywords: CLL, Chimeric T-cell receptor, CD23, Immunotherapy, Cell Therapy
暂无分享,去创建一个
M. Ponzoni | A. Biondi | B. Savoldo | G. Dotti | V. Hoyos | P. Ghia | E. Biagi | V. Agostoni | V. Marin | Irene | M. Parma | S. Tettamanti | G. G. Attianese | Pizzitola | S. Mariat | Bertilaccio | Sarah Tettamanti | Irène | Valentina Agostoni
[1] C. Aspord,et al. Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells , 2010, Journal of biomedicine & biotechnology.
[2] G. Simonetti,et al. A novel Rag2-/-gammac-/--xenograft model of human CLL. , 2010, Blood.
[3] Arturo Molina,et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. , 2010, Blood.
[4] T. Lin. New Agents in Chronic Lymphocytic Leukemia , 2010, Current hematologic malignancy reports.
[5] M. Brenner,et al. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". , 2009, Human gene therapy.
[6] D. Campana,et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] Michel Sadelain,et al. The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.
[8] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[9] H. Heslop,et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. , 2008, Blood.
[10] H. Heslop,et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.
[11] J. Byrd,et al. Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia , 2007, Clinical Cancer Research.
[12] A. Biondi,et al. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. , 2007, Haematologica.
[13] H. Heslop,et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.
[14] David D. Smith,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.
[15] M. Brenner,et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.
[16] A. Biondi,et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. , 2006, Experimental hematology.
[17] F. Ravandi,et al. Immune defects in patients with chronic lymphocytic leukemia , 2006, Cancer Immunology, Immunotherapy.
[18] M. Andreeff,et al. Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia , 2005, Clinical Cancer Research.
[19] P. Bierman,et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Roman Rydzanicz,et al. Assembly PCR oligo maker: a tool for designing oligodeoxynucleotides for constructing long DNA molecules for RNA production , 2005, Nucleic Acids Res..
[21] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Mayr,et al. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. , 2005, Experimental hematology.
[23] David D. Smith,et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. , 2005, Blood.
[24] M. Papamichail,et al. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes , 2004, Cancer Immunology, Immunotherapy.
[25] M. Goller,et al. Regulation of CD23 isoforms on B-chronic lymphocytic leukemia. , 2002, Leukemia research.
[26] V. Diehl,et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] M. Dettke,et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. , 2002, Blood.
[28] Richard Greil,et al. The Role of Soluble CD23 in Distinguishing Stable and Progressive Forms of B-chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[29] C. Bollard,et al. Targeting of GD2‐positive tumor cells by human T lymphocytes engineered to express chimeric T‐cell receptor genes , 2001, International journal of cancer.
[30] A. Wotherspoon,et al. High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. , 1999, Human pathology.
[31] P. Circosta,et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. , 1999, Leukemia research.
[32] C. D. Wu,et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] D. Earnshaw,et al. CD23 (FcepsilonRII) release from cell membranes is mediated by a membrane-bound metalloprotease. , 1998, The Biochemical journal.
[34] V. Diehl,et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA , 1998, Gene Therapy.
[35] H. Heslop,et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. , 1995, Journal of hematotherapy.
[36] S. Fournier,et al. The two CD23 isoforms display differential regulation in chronic lymphocytic leukaemia , 1995, British journal of haematology.
[37] C. Gasche,et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] H. Eibel,et al. Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development. , 1994, Journal of immunology.
[39] S. Fournier,et al. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. , 1992, The Journal of clinical investigation.
[40] J. Banchereau,et al. Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation. , 1991, Journal of immunology.
[41] R. Hardy,et al. Fc epsilon receptor, a specific differentiation marker transiently expressed on mature B cells before isotype switching , 1986, The Journal of experimental medicine.
[42] E. Jaffe,et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. , 2000, Blood.
[43] J. Roliński,et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. , 2008, Oncology reports.
[44] H. Döhner,et al. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids , 2007, Leukemia.
[45] S. Molica,et al. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. , 1996, Haematologica.
[46] S. Fournier,et al. The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemic cells is associated with an abnormally low CD23 upregulation by IL-4: comparison with their normal cellular counterparts. , 1991, Leukemia research.